Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules 2024
10.11106/ijt.2024.17.1.208
- Author:
Young Joo PARK
1
;
Eun Kyung LEE
;
Young Shin SONG
;
Su Hwan KANG
;
Bon Seok KOO
;
Sun Wook KIM
;
Dong Gyu NA
;
Seung-Kuk BAEK
;
So Won OH
;
Min Kyoung LEE
;
Sang-Woo LEE
;
Young Ah LEE
;
Yong Sang LEE
;
Ji Ye LEE
;
Dong-Jun LIM
;
Leehi JOO
;
Yuh-Seog JUNG
;
Chan Kwon JUNG
;
Yoon Young CHO
;
Yun Jae CHUNG
;
Won Bae KIM
;
Ka Hee YI
;
Ho-Cheol KANG
;
Do Joon PARK
Author Information
1. Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
- Publication Type:REVIEW ARTICLES
- From:International Journal of Thyroidology
2024;17(1):208-244
- CountryRepublic of Korea
- Language:EN
-
Abstract:
Thyroid nodules represent a prevalent condition that is detectable via palpation or ultrasound. In recent years, there has been a paradigm shift toward enhanced diagnostic precision and less aggressive therapeutic approaches, highlighting the growing necessity for tailored clinical recommendations to optimize patient outcomes. The Korean Thyroid Association (KTA) has developed guidelines for managing patients with thyroid nodules, following a comprehensive review by task force members of the relevant literature identified via electronic database searches. The recommendations are provided with a level of recommendation for each section. The guidelines encompass thyroid cancer screening in high-risk groups, appropriate diagnostic methods for thyroid nodules, role of pathologic and molecular marker testing in making a diagnosis, long-term follow-up and treatment of benign thyroid nodules, and special considerations for pregnant women. The major revisions that were made in the 2023 guidelines were the definition of high-risk groups for thyroid cancer screening, application of the revised Korean Thyroid Imaging Reporting and Data System (K-TIRADS), addition of the role of core needle biopsy and molecular marker tests, application of active surveillance in patients with low-risk papillary thyroid microcarcinoma, and updated indications for nonsurgical treatment of benign thyroid nodules. In the 2024 revision of the KTA guidelines for thyroid cancer, the evidence for some recommendations has been updated to address the tumor size in the context of active surveillance in patients with low-risk thyroid cancer and the surgical size cutoff. These evidence-based recommendations serve to inform clinical decision-making in the management of thyroid nodules, thereby facilitating the delivery of optimal and efficacious treatments to patients.
